Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices
Source: Senate LDA
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated against policies that include international reference pricing
Discussed and informed on the Biocom CA 2026 Life Science Economic Impact Report Advocated against policies that would undermine economic development in the life sciences (i.e., MFN, MDPNP)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care
Discussed and informed on the Biocom CA 2026 Life Science Economic Impact Report Advocated against policies that would undermine economic development in the life sciences (i.e., MFN, MDPNP)
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocated for SBIR/STTR reauthorization Discussed and informed on the Biocom CA 2025 Life Science Economic Impact Report
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices Responded to OSTP RFI on strengthening America's global competitiveness
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions Advocated for reauthorization of SBIR/STTR programs
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program Discussed FDA's PreCheck and Commissioners National Priority Voucher Programs
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB and submitted response letter to USPTO Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices Responded to OSTP RFI on strengthening America's global competitiveness
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions Advocated for a continuing resolution and minibus to fund the government Advocated for reauthorization of SBIR/STTR programs
Advocated for SBIR/STTR reauthorization Discussed and informed on the Biocom CA 2025 Life Science Economic Impact Report
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program Advocated for the ORPHAN Cures Act, and related language, after previous IRA mitigation initiatives Hosted a briefing on the biotech industry Discussed the Administrations health prioritie Discussed FDA's PreCheck and Commissioners National Priority Voucher Programs
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred Advocated to amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit Advocated for an increase in the SALT cap
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Advocated on the difficulties of onshoring too quickly and expressed the desire to, but through proper channels Advocated against steep tariffs on pharmaceuticals, APIs, and med devices
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions Advocated for a continuing resolution to fund the government
Advocated for SBIR/STTR reauthorization Discussed and informed on the Biocom CA 2025 Life Science Economic Impact Report Co-hosted a briefing on SBIR/STTR reauthorization
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program Advocated for the ORPHAN Cures Act, and related language, after previous IRA mitigation initiatives
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter Advocated for granting injunctions with respect to infringing conduct once a court enters a final judgement against an infringer.
Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter
Advocated for permanent adoption of the telehealth flexibilities created during the COVID-19 public health emergency Advocated for changes to the drug pricing provisions of the Inflation Reduction Act Advocated for public health considerations in federal privacy legislation Advocated for the adoption of a Transitional Coverage for Emerging Technologies payment pathway for medical devices. Advocated for policies that advance the use of emerging technologies, including AI in health care Advocated for reauthorization of the Rare Pediatric Disease Priority Review Voucher program
Advocated for the protection of Intellectual Property rights Expressed opposition to FDA and PTO activities that would undermine IP rights. Advocated against policies that would negatively impact technology transfer programs at universities Advocated in support of less restrictive merger & acquisition policies in life sciences Advocated for a reformed PTAB Advocated for Section 101 reforms that provide clearer guidelines on what constitutes patentable subject matter
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred Advocated to amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit Advocated for an increase in the SALT cap
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain Submitted written comments on Sec 232
Advocated for SBIR/STTR reauthorization Discussed and informed on the Biocom CA 2025 Life Science Economic Impact Report
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred Advocated to amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocated to reverse a tax provision preventing businesses from deducting their R&D expenses in the same year they were incurred Advocated to amend the Internal Revenue Code of 1986 to restore the amount of the orphan drug tax credit
Advocated for strengthening the US supply chain and mitigating supply chain disruptions of essential products Advocated for a strong and diverse global supply chain
Advocated for increased discretionary funding for HHS appropriations, including NIH, CDC, BARDA, SNS, CCBHC Advocated for increased discretionary funding for FDA appropriations Advocated for increased discretionary funding for all federally funded scientific research institutions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE